Literature DB >> 17083061

Genetic clamping of renin gene expression induces hypertension and elevation of intrarenal Ang II levels of graded severity in Cyp1a1-Ren2 transgenic rats.

Kenneth D Mitchell1, Stuart J Bagatell, Chad S Miller, Cynthia R Mouton, Dale M Seth, John J Mullins.   

Abstract

INTRODUCTION: Transgenic rats with inducible angiotensin II (Ang II)-dependent hypertension (strain name: TGR[Cyp1a1-Ren2]) were generated by inserting the mouse Ren2 renin gene, fused to the cytochrome P450 1a1 (Cyp1a1) promoter, into the genome of the rat. The present study was performed to characterise the changes in plasma and kidney tissue Ang II levels and in renal haemodynamic function in Cyp1a1-Ren2 rats following induction of either slowly developing or malignant hypertension in these transgenic rats.
MATERIALS AND METHODS: Arterial blood pressure (BP) and renal haemodynamics and excretory function were measured in pentobarbital sodium-anaesthetised Cyp1a1- Ren2 rats fed a normal diet containing either a low dose (0.15%, w/w for 1415 days) or high dose (0.3%, w/w for 1112 days) of the aryl hydrocarbon indole-3-carbinol (I3C) to induce slowly developing and malignant hypertension, respectively. In parallel experiments, arterial blood samples and kidneys were harvested for measurement of Ang II levels by radioimmunoassay.
RESULTS: Dietary I3C increased plasma renin activity (PRA), plasma Ang II levels, and arterial BP in a dose-dependent manner. Induction of different fixed levels of renin gene expression and PRA produced hypertensive phenotypes of varying severity with rats developing either mild or malignant forms of hypertensive disease. Administration of I3C, at a dose of 0.15% (w/w), induced a slowly developing form of hypertension whereas administration of a higher dose (0.3%) induced a more rapidly developing hypertension and the clinical manifestations of malignant hypertension including severe weight loss. Both hypertensive phenotypes were characterised by reduced renal plasma flow, increased filtration fraction, elevated PRA, and increased plasma and intrarenal Ang II levels. These I3C-induced changes in renal haemodynamics, PRA and kidney Ang II levels were more pronounced in Cyp1a1-Ren2 rats with malignant hypertension. Chronic administration of the AT1-receptor antagonist, hypertension, the associated changes in renal haemodynamics, and the augmentation of intrarenal Ang II levels.
CONCLUSIONS: Activation of AT1-receptors by Ang II generated as a consequence of induction of the Cyp1a1-Ren2 transgene mediates the increased arterial pressure and the associated reduction of renal haemodynamics and enhancement of intrarenal Ang II levels in hypertensive Cyp1a1-Ren2 transgenic rats.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17083061     DOI: 10.3317/jraas.2006.013

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  34 in total

1.  Enhanced urinary angiotensinogen excretion in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension.

Authors:  Carlo J Milani; Hiroyuki Kobori; John J Mullins; Kenneth D Mitchell
Journal:  Am J Med Sci       Date:  2010-11       Impact factor: 2.378

2.  Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension.

Authors:  Zuzana Honetschlägerová; Zuzana Husková; Zdeňka Vaňourková; Alexandra Sporková; Herbert J Kramer; Sung Hee Hwang; Hsing-Ju Tsai; Bruce D Hammock; John D Imig; Luděk Červenka; Libor Kopkan
Journal:  J Physiol       Date:  2011-01-01       Impact factor: 5.182

3.  Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats.

Authors:  Zuzana Honetschlägerová; Alexandra Sporková; Libor Kopkan; Zuzana Husková; Sung H Hwang; Bruce D Hammock; John D Imig; Herbert J Kramer; Petr Kujal; Zdenka Vernerová; Věra C Chábová; Vladimír Tesař; Luděk Cervenka
Journal:  J Hypertens       Date:  2011-08       Impact factor: 4.844

4.  Angiotensin II type 1 receptor-mediated augmentation of urinary excretion of endogenous angiotensin II in Val5-angiotensin II-infused rats.

Authors:  Weijian Shao; Dale M Seth; L Gabriel Navar
Journal:  Hypertension       Date:  2010-07-12       Impact factor: 10.190

5.  Chronic direct renin inhibition with aliskiren prevents the development of hypertension in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent hypertension.

Authors:  Lily Huang; Catherine G Howard; Kenneth D Mitchell
Journal:  Am J Med Sci       Date:  2012-10       Impact factor: 2.378

6.  On the Origin of Urinary Renin: A Translational Approach.

Authors:  Lodi C W Roksnoer; Bart F J Heijnen; Daisuke Nakano; Janos Peti-Peterdi; Stephen B Walsh; Ingrid M Garrelds; Jeanette M G van Gool; Robert Zietse; Harry A J Struijker-Boudier; Ewout J Hoorn; A H Jan Danser
Journal:  Hypertension       Date:  2016-02-29       Impact factor: 10.190

7.  Transient induction of ANG II-dependent malignant hypertension causes sustained elevation of blood pressure and augmentation of the pressor response to ANG II in CYP1A1-REN2 transgenic rats.

Authors:  Catherine G Howard; John J Mullins; Kenneth D Mitchell
Journal:  Am J Med Sci       Date:  2010-06       Impact factor: 2.378

8.  Direct renin inhibition with aliskiren normalizes blood pressure in Cyp1a1-Ren2 transgenic rats with inducible angiotensin ii-dependent malignant hypertension.

Authors:  Catherine G Howard; John J Mullins; Kenneth D Mitchell
Journal:  Am J Med Sci       Date:  2011-05       Impact factor: 2.378

9.  Angiotensin-converting enzyme is a modifier of hypertensive end organ damage.

Authors:  Xiaojun Liu; Christopher O C Bellamy; Matthew A Bailey; Linda J Mullins; Donald R Dunbar; Christopher J Kenyon; Gillian Brooker; Surasak Kantachuvesiri; Klio Maratou; Ali Ashek; Allan F Clark; Stewart Fleming; John J Mullins
Journal:  J Biol Chem       Date:  2009-03-23       Impact factor: 5.157

10.  Lack of cardiac fibrosis in a new model of high prorenin hyperaldosteronism.

Authors:  Jörg Peters; Torsten Schlüter; Thomas Riegel; Barbara S Peters; Andreas Beineke; Ulrike Maschke; Norbert Hosten; John J Mullins; Rainer Rettig
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-09-11       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.